FI4009978T3 - Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon - Google Patents

Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon Download PDF

Info

Publication number
FI4009978T3
FI4009978T3 FIEP20758407.9T FI20758407T FI4009978T3 FI 4009978 T3 FI4009978 T3 FI 4009978T3 FI 20758407 T FI20758407 T FI 20758407T FI 4009978 T3 FI4009978 T3 FI 4009978T3
Authority
FI
Finland
Prior art keywords
sepiapterin
mir
pharmaceutically acceptable
mixed crystal
acceptable salt
Prior art date
Application number
FIEP20758407.9T
Other languages
English (en)
Finnish (fi)
Inventor
Eleonora Mezzaroma
Christopher Rabender
Ross Mikkelsen
Vasily Yakovlev
Neil Smith
Original Assignee
Ptc Therapeutics Mp Inc
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc, Univ Virginia Commonwealth filed Critical Ptc Therapeutics Mp Inc
Application granted granted Critical
Publication of FI4009978T3 publication Critical patent/FI4009978T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
FIEP20758407.9T 2019-08-05 2020-08-05 Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon FI4009978T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Publications (1)

Publication Number Publication Date
FI4009978T3 true FI4009978T3 (fi) 2024-11-01

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20758407.9T FI4009978T3 (fi) 2019-08-05 2020-08-05 Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon

Country Status (21)

Country Link
US (1) US20220273661A1 (https=)
EP (2) EP4454712A3 (https=)
JP (2) JP7642611B2 (https=)
CN (2) CN119837879A (https=)
AU (1) AU2020324435B2 (https=)
BR (1) BR112022002029A2 (https=)
CA (1) CA3146477A1 (https=)
DK (1) DK4009978T3 (https=)
ES (1) ES2994060T3 (https=)
FI (1) FI4009978T3 (https=)
HR (1) HRP20241653T1 (https=)
HU (1) HUE069012T2 (https=)
IL (1) IL290321B1 (https=)
LT (1) LT4009978T (https=)
MX (1) MX2022001535A (https=)
PL (1) PL4009978T3 (https=)
PT (1) PT4009978T (https=)
RS (1) RS66096B1 (https=)
SI (1) SI4009978T1 (https=)
SM (1) SMT202500089T1 (https=)
WO (1) WO2021026247A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
CN112654356A (zh) 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
EP1696877A4 (en) 2003-11-13 2010-06-09 Gen Hospital Corp PROCESS FOR PAIN TREATMENT
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
KR20160068776A (ko) 2013-09-13 2016-06-15 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 방사선 효과의 완화 및 예방을 위한 조성물의 제조 및 용도
WO2016054458A1 (en) 2014-10-02 2016-04-07 Cytosorbents Corporation Use of gastroinstestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物

Also Published As

Publication number Publication date
AU2020324435B2 (en) 2026-03-19
IL290321B1 (en) 2026-04-01
PT4009978T (pt) 2024-11-05
RS66096B1 (sr) 2024-11-29
CA3146477A1 (en) 2021-02-11
EP4009978B1 (en) 2024-09-25
EP4454712A2 (en) 2024-10-30
EP4454712A3 (en) 2025-01-01
SMT202500089T1 (it) 2025-03-12
IL290321A (en) 2022-04-01
CN119837879A (zh) 2025-04-18
MX2022001535A (es) 2022-03-04
PL4009978T3 (pl) 2025-02-24
JP2022543655A (ja) 2022-10-13
ES2994060T3 (en) 2025-01-16
AU2020324435A1 (en) 2022-02-24
DK4009978T3 (da) 2024-10-14
US20220273661A1 (en) 2022-09-01
WO2021026247A1 (en) 2021-02-11
LT4009978T (lt) 2024-11-25
HRP20241653T1 (hr) 2025-04-25
JP2025098011A (ja) 2025-07-01
BR112022002029A2 (pt) 2022-06-07
HUE069012T2 (hu) 2025-02-28
SI4009978T1 (sl) 2025-03-31
CN114555090A (zh) 2022-05-27
EP4009978A1 (en) 2022-06-15
CN114555090B (zh) 2024-12-17
JP7642611B2 (ja) 2025-03-10

Similar Documents

Publication Publication Date Title
FI4009978T3 (fi) Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon
Tao et al. Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin
Brücken et al. Dose dependent neuroprotection of the noble gas argon after cardiac arrest in rats is not mediated by KATP—channel opening
FI3849534T3 (fi) Yhdistelmähoidot
FI3902547T3 (fi) Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
Wu et al. Protective effects of aloperin on monocroline-induced pulmonary hypertension via regulation of Rho A/Rho kinsase pathway in rats
JP2014139255A5 (https=)
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
JP2017536380A5 (https=)
FI3989962T3 (fi) Asetyylileusiinia ja miglustaattia sisältävä yhdistelmähoito lysosomaalisen kertymäsairauden hoidossa
US10639296B2 (en) Methods to mitigate injury from radiation exposure
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
Makedonova et al. Studying clinical and pathomorphological changes in gingival tissues when applying platelet-rich autoplasma regenerative method
JPWO2021026247A5 (https=)
CN107441071A (zh) 一种芳姜黄酮在制备治疗和/或预防银屑病药物中的应用
Wang et al. Tissue injury by hot fluid containing nitrogen mustard
FI3261625T3 (fi) Kolmena pulssina vapauttavia stimulanttiformulaatioita
Touma et al. A case of pheochromocytoma presenting with cardiopulmonary arrest
Vadivelan et al. The ‘golden hour’in paraquat poisoning
JP2008518020A5 (https=)
CN118831115B (zh) 用于治疗和/或预防脓毒症的中药组合物、药物制剂及用途
CN106727504B (zh) 辛伐他汀在制备预防高分压氧导致的肺型氧中毒的药物中的应用
CN119074852B (zh) 用于清肺利咽的中药组合物、药物制剂及用途
RU2538433C1 (ru) Фармацевтическая композиция для профилактики и лечения инфекционно-воспалительных заболеваний различной этиологии путем оромукозного введения